Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients
Affiliations
- PMID: 8962235
Item in Clipboard
Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients
Transplant Proc.
1996 Dec.
No abstract available
Similar articles
-
Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.Transplant Proc. 1995 Feb;27(1):45-9. Transplant Proc. 1995. PMID: 7533415 Clinical Trial. No abstract available.
-
Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.Transplant Proc. 2005 May;37(4):1691-2. doi: 10.1016/j.transproceed.2005.03.130. Transplant Proc. 2005. PMID: 15919432
-
Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.Transplant Proc. 1996 Apr;28(2):1011-3. Transplant Proc. 1996. PMID: 8623212 No abstract available.
-
Clinical use of FK 506 in liver transplantation.Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.
-
Neoral is superior to FK 506 in liver transplantation.Transplant Proc. 1998 Aug;30(5):1812-5. doi: 10.1016/s0041-1345(98)00442-4. Transplant Proc. 1998. PMID: 9723293 Review. No abstract available.
Cited by
-
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.Liver Transpl. 2001 Jul;7(7):623-30. doi: 10.1053/jlts.2001.25364. Liver Transpl. 2001. PMID: 11460230 Free PMC article.
-
Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.Drugs. 1997 Dec;54(6):925-75. doi: 10.2165/00003495-199754060-00009. Drugs. 1997. PMID: 9421697 Review.
MeSH terms
Substances
LinkOut - more resources
Medical